Table 5.
Multivariate analysis of factors associated with LTFU among HIV-infected adults on antiretroviral therapy
| Multivariate Results (n = 23890) | ||||||||
|---|---|---|---|---|---|---|---|---|
| 6 months | 12 months | 24 months | 36 months | |||||
| aOR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value | |
| Gender | ||||||||
| Male | 1.23 (1.12–1.36) | < 0.001 | 1.19 (1.10–1.29) | < 0.001 | 1.19 (1.1–1.27) | < 0.001 | 1.19 (1.12–1.27) | < 0.001 |
| Female | Ref | Ref | Ref | Ref | ||||
| BMI | ||||||||
| < 18.5 | 1.52 (1.3–1.78) | < 0.001 | 2.51 (1.88–3.36) | < 0.001 | 2.02 (1.63–2.5) | < 0.001 | 1.68 (1.39–2.02) | < 0.001 |
| 18.5–24.9 | Ref | Ref | Ref | Ref | ||||
| 25–29.9 | 0.58 (0.43–0.77) | < 0.001 | 0.61 (0.49–0.77) | < 0.001 | 0.66 (0.55–0.79) | < 0.001 | 0.69 (0.6–0.79) | < 0.001 |
| 30+ | 0.50 (0.37–0.69) | < 0.001 | 0.55 (0.42–0.71) | < 0.001 | 0.62 (0.52–0.75) | < 0.001 | 0.69 (0.58–0.82) | < 0.001 |
| Age | ||||||||
| 20–35 | 1.23 (1.12–1.35) | < 0.001 | 1.36 (1.26–1.47) | < 0.001 | 1.47 (1.37–1.57) | < 0.001 | 1.49 (1.40–1.59) | < 0.001 |
| 36–50 | Ref | Ref | Ref | Ref | ||||
| 51+ | 1.03 (0.88–1.2) | 0.719 | 1.00 (0.87–1.14) | 0.960 | 0.98 (0.87–1.1) | 0.665 | 0.99 (0.89–1.10) | 0.803 |
| Marital Status | ||||||||
| Single | 1.34 (1.19–1.51) | < 0.001 | 1.31 (1.18–1.45) | < 0.001 | 1.26 (1.15–1.38) | < 0.001 | 1.34 (1.23–1.45) | < 0.001 |
| Divorced | 1.35 (1.19–1.53) | < 0.001 | 1.31 (1.17–1.46) | < 0.001 | 1.30 (1.19–1.43) | < 0.001 | 1.25 (1.15–1.36) | < 0.001 |
| Married | Ref | Ref | Ref | Ref | ||||
| Widowed | 1.01 (0.87–1.18) | 0.859 | 0.99 (0.87–1.12) | 0.814 | 1.02 (0.91–1.14) | 0.726 | 1.03 (0.93–1.14) | 0.555 |
| CD4 | ||||||||
| 0–250 | 1.34 (1.16–1.55) | < 0.001 | 1.33 (1.17–1.5) | < 0.001 | 1.15 (1.05–1.27) | 0.004 | 1.18 (1.08–1.29) | < 0.001 |
| 251–500 | Ref | Ref | Ref | Ref | ||||
| Above 500 | 1.42 (0.81–2.49) | 0.215 | 1.22 (0.73–2.05) | 0.448 | 1.42 (0.93–2.16) | 0.102 | 1.33 (0.90–1.96) | 0.149 |
| Regimen Started | ||||||||
| D4T-based | Ref | Ref | Ref | Ref | ||||
| ABC-based | 2.37 (1.82–3.08) | < 0.001 | 2.44 (1.93–3.09) | < 0.001 | 2.33 (1.87–2.90) | < 0.001 | 2.17 (1.75–2.69) | < 0.001 |
| AZT-based | 0.74 (0.65–0.83) | < 0.001 | 0.75 (0.67–0.83) | < 0.001 | 0.78 (0.71–0.85) | < 0.001 | 0.85 (0.79–0.93) | < 0.001 |
| TDF-based | 0.62 (0.55–0.69) | < 0.001 | 0.67 (0.61–0.74) | < 0.001 | 0.73 (0.68–0.8) | < 0.001 | 0.86 (0.80–0.92) | < 0.001 |
| Baseline WHO Stage | ||||||||
| Stage I | Ref | Ref | Ref | Ref | ||||
| Stage II | 1.03 (0.87–1.22) | 0.732 | 1.08 (0.95–1.24) | 0.242 | 1.07 (0.96–1.19) | 0.251 | 1.07 (0.98–1.17) | 0.147 |
| Stage III | 1.34 (1.14–1.57) | < 0.001 | 1.31 (1.16–1.48) | < 0.001 | 1.25 (1.13–1.39) | < 0.001 | 1.22 (1.12–1.34) | < 0.001 |
| Stage IV | 1.83 (1.48–2.26) | < 0.001 | 1.57 (1.31–1.88) | < 0.001 | 1.38 (1.17–1.62) | < 0.001 | 1.34 (1.15–1.57) | < 0.001 |